stoxline Quote Chart Rank Option Currency Glossary
  
Azitra, Inc. (AZTR)
0.2276  -0.004 (-1.64%)    07-14 16:00
Open: 0.2314
High: 0.2367
Volume: 1,303,113
  
Pre. Close: 0.2314
Low: 0.22
Market Cap: 4(M)
Technical analysis
2025-07-14 4:38:25 PM
Short term     
Mid term     
Targets 6-month :  0.35 1-year :  0.42
Resists First :  0.3 Second :  0.36
Pivot price 0.24
Supports First :  0.21 Second :  0.18
MAs MA(5) :  0.23 MA(20) :  0.25
MA(100) :  0.29 MA(250) :  0.47
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  26.6 D(3) :  27.1
RSI RSI(14): 37.5
52-week High :  12 Low :  0.21
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AZTR ] has closed above bottom band by 8.0%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.24 - 0.24 0.24 - 0.24
Low: 0.22 - 0.22 0.22 - 0.22
Close: 0.22 - 0.23 0.23 - 0.23
Company Description

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Headline News

Thu, 03 Jul 2025
Azitra Inc Approves Increase in Common Stock Shares - TipRanks

Wed, 18 Jun 2025
Azitra Inc Plans Stock Increase at Annual Meeting - TipRanks

Tue, 17 Jun 2025
Azitra Inc Announces Positive Phase 1b Trial Results - TipRanks

Tue, 17 Jun 2025
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome - PR Newswire

Tue, 13 May 2025
Azitra Advances Novel Skin Disease Treatments: Key Trial Results Expected in 2025 - Stock Titan

Thu, 24 Apr 2025
$20M Strategic Investment Accelerates Azitra's Breakthrough Treatments for 150,000 Rare Disease Patients - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 8 (M)
Held by Insiders 6.83e+006 (%)
Held by Institutions 10.6 (%)
Shares Short 311 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.012e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -35 %
Return on Assets (ttm) 470.3 %
Return on Equity (ttm) -93.5 %
Qtrly Rev. Growth 408200 %
Gross Profit (p.s.) 0.02
Sales Per Share 0.05
EBITDA (p.s.) -0.63
Qtrly Earnings Growth 92.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 4.39
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 208380
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android